{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:30:59Z","timestamp":1793943059228,"version":"4.8.0"},"reference-count":148,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100030679","name":"Mundipharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030679","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003086","name":"Basque Government","doi-asserted-by":"publisher","award":["GIC21\/24 IT1607-22"],"award-info":[{"award-number":["GIC21\/24 IT1607-22"]}],"id":[{"id":"10.13039\/501100003086","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030732","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030732","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005612","name":"Shionogi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Iberoamericana de Micolog\u00eda"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.riam.2026.02.001","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T15:59:48Z","timestamp":1774972788000},"page":"55-70","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Antifungal activity of rezafungin in invasive candidiasis: From bench to bed"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0438-2248","authenticated-orcid":false,"given":"Guillermo","family":"Quind\u00f3s","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8915-0683","authenticated-orcid":false,"given":"Carolina","family":"Garcia-Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0141-1893","authenticated-orcid":false,"given":"Xabier","family":"Martin-Martitegui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6593-5486","authenticated-orcid":false,"given":"Rafael","family":"Zaragoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.riam.2026.02.001_bib0745","doi-asserted-by":"crossref","first-page":"7844","DOI":"10.1002\/cam4.5551","article-title":"Chimeric antigen receptor T (CAR-T) cells: novel cell therapy for hematological malignancies","volume":"12","author":"Abbasi","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.riam.2026.02.001_bib0750","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1002\/ijc.33119","article-title":"Risk of QTc prolongation among cancer patients treated with tyrosine kinase inhibitors","volume":"147","author":"Abu Rmilah","year":"2020","journal-title":"Int J Cancer"},{"key":"10.1016\/j.riam.2026.02.001_bib0755","article-title":"Expanded access use of rezafungin for salvage therapy of invasive Candida glabrata infection: a case report","volume":"8","author":"Adeel","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.riam.2026.02.001_bib0760","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00847-24","article-title":"Case commentary: extending our therapeutic range against multidrug-resistant Candida","volume":"68","author":"Adelman","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2026.02.001_bib0765","series-title":"Agencia Espa\u00f1ola de Medicamentos y de Productos Sanitarios. Informe de Posicionamiento Terap\u00e9utico de rezafungina (Rezzayo\u00ae) en el tratamiento de la candidiasis invasiva en adultos","year":"2024"},{"key":"10.1016\/j.riam.2026.02.001_bib0770","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.687458","article-title":"Targeting Bruton's tyrosine kinase in CLL","volume":"12","author":"Ahn","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.riam.2026.02.001_bib0775","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s40262-024-01461-5","article-title":"Echinocandins pharmacokinetics: a comprehensive review of micafungin, caspofungin, anidulafungin, and rezafungin population pharmacokinetic models and dose optimization in special populations","volume":"64","author":"Albanell-Fern\u00e1ndez","year":"2025","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.riam.2026.02.001_bib0780","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/jac\/dkae415","article-title":"The distinctive pharmacokinetic profile of rezafungin, a long-acting echinocandin developed in the era of modern pharmacometrics","volume":"80","author":"Andes","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.riam.2026.02.001_bib0785","first-page":"e52050","article-title":"Risk of severe infections secondary to the use of targeted therapies in hematological malignancies","volume":"16","author":"Andreescu","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.riam.2026.02.001_bib0790","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.jinf.2023.08.001","article-title":"European candidaemia is characterised by notable differential epidemiology and susceptibility pattern: Results from the ECMM Candida III study","volume":"87","author":"Arendrup","year":"2023","journal-title":"J Infect"},{"key":"10.1016\/j.riam.2026.02.001_bib0795","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.cmi.2018.02.021","article-title":"Multicentre determination of rezafungin (CD101) susceptibility of Candida species by the EUCAST method","volume":"24","author":"Arendrup","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.riam.2026.02.001_bib0800","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3390\/jof10090617","article-title":"In vivo efficacy of rezafungin, anidulafungin, caspofungin, and micafungin against four Candida auris clades in a neutropenic mouse bloodstream infection model","volume":"10","author":"Bal\u00e1zsi","year":"2024","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.riam.2026.02.001_bib0805","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/s13054-019-2497-3","article-title":"Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: results of the EUCANDICU project","volume":"23","author":"Bassetti","year":"2019","journal-title":"Crit Care"},{"key":"10.1016\/j.riam.2026.02.001_bib0810","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/17425255.2024.2424899","article-title":"Rezafungin acetate for the treatment of candidemia and invasive candidiasis: a pharmacokinetic evaluation","volume":"21","author":"Bassetti","year":"2025","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.riam.2026.02.001_bib0815","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s40265-019-01127-8","article-title":"Adverse effects associated with long-term administration of azole antifungal agents","volume":"79","author":"Benitez","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.riam.2026.02.001_bib0820","doi-asserted-by":"crossref","first-page":"e0244921","DOI":"10.1128\/jcm.02449-21","article-title":"Evaluation of rezafungin provisional CLSI Clinical Breakpoints and Epidemiological Cutoff Values tested against a worldwide collection of contemporaneous invasive fungal isolates (2019\u20132020)","volume":"60","author":"Carvalhaes","year":"2022","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.riam.2026.02.001_bib0825","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1111\/myc.13490","article-title":"Evaluation of the post-antifungal effect of rezafungin and micafungin against Candida albicans, Candida parapsilosis and Candida glabrata","volume":"65","author":"Carvalhaes","year":"2022","journal-title":"Mycoses"},{"key":"10.1016\/j.riam.2026.02.001_bib0830","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae702","article-title":"Activity of rezafungin against echinocandin non-wild type Candida glabrata clinical isolates from a global surveillance program","volume":"12","author":"Castanheira","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.riam.2026.02.001_bib0835","doi-asserted-by":"crossref","DOI":"10.1093\/jacamr\/dlaf040","article-title":"Identification and antifungal susceptibility patterns of reference yeast strains to novel and conventional agents: a comparative study using CLSI EUCAST and Sensititre YeastOne methods","volume":"7","author":"Ceballos-Garzon","year":"2025","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.riam.2026.02.001_bib0840","doi-asserted-by":"crossref","first-page":"e01750","DOI":"10.1128\/AAC.01750-17","article-title":"CD101, a novel echinocandin, possesses potent antibiofilm activity against early and mature Candida albicans biofilms","volume":"62","author":"Chandra","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2026.02.001_bib0845","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1093\/jac\/dkae302","article-title":"Use of echinocandin outpatient parenteral antimicrobial therapy for the treatment of infection caused by Candida spp.: utilization, outcomes and impact of a change to weekly dosing","volume":"79","author":"Clarke","year":"2024","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl. 7","key":"10.1016\/j.riam.2026.02.001_bib0850","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/1469-0691.12039","article-title":"ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients","volume":"18","author":"Cornely","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.riam.2026.02.001_bib0855","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2025.106435","article-title":"Rezafungin in special populations with candidaemia and\/or invasive candidiasis","volume":"90","author":"Cornely","year":"2025","journal-title":"J Infect"},{"key":"10.1016\/j.riam.2026.02.001_bib0860","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(24)00749-7","article-title":"Global guideline for the diagnosis and management of candidiasis: an initiative of the ECMM in cooperation with ISHAM and ASM","author":"Cornely","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.riam.2026.02.001_bib0865","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1093\/cid\/cix033","article-title":"Echinocandins compared to fluconazole for candidemia of a urinary tract source: a propensity score analysis","volume":"64","author":"Cuervo","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.riam.2026.02.001_bib0870","doi-asserted-by":"crossref","first-page":"747","DOI":"10.3390\/jof7090747","article-title":"The long-acting echinocandin, rezafungin, prevents Pneumocystis pneumonia and eliminates Pneumocystis from the lungs in prophylaxis and murine treatment models","volume":"7","author":"Cushion","year":"2021","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.riam.2026.02.001_bib0875","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jtct.2020.10.003","article-title":"American Society of Transplantation and Cellular Therapy series, 2: Management and prevention of aspergillosis in hematopoietic cell transplantation recipients","volume":"27","author":"Dadwal","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.riam.2026.02.001_bib0880","doi-asserted-by":"crossref","first-page":"e428","DOI":"10.1016\/S1473-3099(23)00692-8","article-title":"Global incidence and mortality of severe fungal disease","volume":"24","author":"Denning","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.riam.2026.02.001_bib0885","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.riam.2026.02.001_bib0890","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/myc.13449","article-title":"Let's talk about sex characteristics \u2013 as a risk factor for invasive fungal diseases","volume":"65","author":"Egger","year":"2022","journal-title":"Mycoses"},{"key":"10.1016\/j.riam.2026.02.001_bib0895","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s11046-023-00776-4","article-title":"Predictors for prolonged hospital stay solely to complete intravenous antifungal treatment in patients with candidemia: results from the ECMM Candida III Multinational European Observational Cohort Study","volume":"188","author":"Egger","year":"2023","journal-title":"Mycopathologia"},{"key":"10.1016\/j.riam.2026.02.001_bib0900","doi-asserted-by":"crossref","first-page":"362","DOI":"10.3390\/jof10050362","article-title":"A mini-review of in vitro data for Candida species, including C. auris, isolated during clinical trials of three new antifungals: fosmanogepix, ibrexafungerp, and rezafungin","volume":"10","author":"Espinel-Ingroff","year":"2024","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.riam.2026.02.001_bib0905","unstructured":"EUCAST. Rezafungin Rationale Document from the AFST. Available from: https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Rationale_documents\/Rezafungin_RD_v1.0_final.pdf."},{"key":"10.1016\/j.riam.2026.02.001_bib0910","unstructured":"European Medicines Agency. Cancidas (caspofungin). Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-%20information\/cancidas-epar-product-information_en.pdf."},{"key":"10.1016\/j.riam.2026.02.001_bib0915","unstructured":"European Medicines Agency. Ecalta (anidulafungin). Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ecalta-epar-product-information_en.pdf."},{"key":"10.1016\/j.riam.2026.02.001_bib0920","unstructured":"European Medicines Agency. Mycamine (micafungin). Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/mycamine-epar-product-information_en.pdf."},{"key":"10.1016\/j.riam.2026.02.001_bib0925","unstructured":"European Medicines Agency. Rezzayo (rezafungin). Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/rezzayo."},{"key":"10.1016\/j.riam.2026.02.001_bib0930","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/cpdd.757","article-title":"Lack of effect of rezafungin on QT\/QTc interval in healthy subjects","volume":"9","author":"Flanagan","year":"2020","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.riam.2026.02.001_bib0935","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/phar.2943","article-title":"Phase I study of the pharmacokinetics and safety of rezafungin in subjects with moderate\/severe hepatic impairment and matched control subjects","volume":"44","author":"Flanagan","year":"2024","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.riam.2026.02.001_bib0940","doi-asserted-by":"crossref","first-page":"e0133923","DOI":"10.1128\/spectrum.01339-23","article-title":"Absence of clinically meaningful drug\u2013drug interactions with rezafungin: outcome of investigations","volume":"11","author":"Flanagan","year":"2023","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.riam.2026.02.001_bib0945","unstructured":"Food and Drug Administration. Rezzayo. Available from: https:\/\/www.fda.gov\/media\/180688\/download."},{"key":"10.1016\/j.riam.2026.02.001_bib0950","doi-asserted-by":"crossref","first-page":"e0064623","DOI":"10.1128\/aac.00646-23","article-title":"New perspectives on antimicrobial agents: rezafungin","volume":"69","author":"Forrister","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2026.02.001_bib0955","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s40265-024-02134-0","article-title":"Rezafungin: a review in invasive candidiasis","volume":"85","author":"Fung","year":"2025","journal-title":"Drugs"},{"key":"10.1016\/j.riam.2026.02.001_bib0960","doi-asserted-by":"crossref","first-page":"O50","DOI":"10.1111\/1469-0691.12312","article-title":"A prospective, cohort, multicentre study of candidaemia in hospitalized adult patients with haematological malignancies","volume":"20","author":"Gamaletsou","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.riam.2026.02.001_bib0965","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.cmi.2023.03.016","article-title":"Climate change, animals, and Candida auris: insights into the ecological niche of a new species from a One Health approach","volume":"29","author":"Garcia-Bustos","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.riam.2026.02.001_bib0970","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3390\/jof6040262","article-title":"Rezafungin: mechanisms of action, susceptibility and resistance: similarities and differences with the other echinocandins","volume":"6","author":"Garc\u00eda-Effron","year":"2020","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.riam.2026.02.001_bib0975","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.eimc.2018.03.018","article-title":"Executive summary of clinical practice guideline for the management of invasive diseases caused by Aspergillus: 2018 update by the GEMICOMED-SEIMC\/REIPI","volume":"37","author":"Garcia-Vidal","year":"2019","journal-title":"Enferm Infecc Microbiol Clin (Engl Ed)"},{"key":"10.1016\/j.riam.2026.02.001_bib0980","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1097\/CCM.0000000000002867","article-title":"Initial antifungal strategy reduces mortality in critically ill patients with candidemia: a propensity score-adjusted analysis of a multicenter study","volume":"46","author":"Garnacho-Montero","year":"2018","journal-title":"Crit Care Med"},{"key":"10.1016\/j.riam.2026.02.001_bib0985","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.cmi.2024.08.006","article-title":"ECCMID study groups on Invasive Fungal Infection and Infection in Immunocompromised Hosts. Invasive fungal disease in the immunocompromised host: changing epidemiology, new antifungal therapies, and management challenges","volume":"31","author":"Giannella","year":"2025","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.riam.2026.02.001_bib0990","doi-asserted-by":"crossref","DOI":"10.1007\/s10096-025-05117-5","article-title":"Salvage therapy of complicated Candida albicans spondylodiscitis with Rezafungin","author":"Grasselli Kmet","year":"2025","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.riam.2026.02.001_bib0995","first-page":"527","article-title":"Cost-effectiveness of three echinocandins and fluconazole in the treatment of candidemia and\/or invasive candidiasis in nonneutropenic adult patients","volume":"7","author":"Grau","year":"2015","journal-title":"Clinicoecon Outcomes Res"},{"key":"10.1016\/j.riam.2026.02.001_bib1000","doi-asserted-by":"crossref","first-page":"101347","DOI":"10.1016\/j.mam.2025.101347","article-title":"Duration of systemic antifungal therapy for patients with invasive fungal diseases: a reassessment","volume":"103","author":"Gressens","year":"2025","journal-title":"Mol Aspects Med"},{"key":"10.1016\/j.riam.2026.02.001_bib1005","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1093\/jac\/dky153","article-title":"Evaluation of the efficacy of rezafungin, a novel echinocandin, in the treatment of disseminated Candida auris infection using an immunocompromised mouse model","volume":"73","author":"Hager","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.riam.2026.02.001_bib1010","doi-asserted-by":"crossref","first-page":"e02438-19","DOI":"10.1128\/AAC.02438-19","article-title":"Rezafungin in vitro activity against contemporary Nordic clinical Candida isolates and Candida auris determined by the EUCAST reference method","volume":"64","author":"Helleberg","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2026.02.001_bib1015","doi-asserted-by":"crossref","first-page":"e0007423","DOI":"10.1128\/cmr.00074-23","article-title":"Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease","volume":"37","author":"Hoenigl","year":"2024","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.riam.2026.02.001_bib1020","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1186\/s13054-024-05117-5","article-title":"Rezafungin versus caspofungin for patients with candidaemia or invasive candidiasis in the intensive care unit: pooled analyses of the ReSTORE and STRIVE randomised trials","volume":"28","author":"Honor\u00e9","year":"2024","journal-title":"Crit Care"},{"issue":"Suppl. 1","key":"10.1016\/j.riam.2026.02.001_bib1025","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/ofid\/ofab466.1176","article-title":"982. Effect of hepatic impairment on the safety and pharmacokinetics of rezafungin","volume":"8","author":"Huguet","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.riam.2026.02.001_bib1030","doi-asserted-by":"crossref","first-page":"727","DOI":"10.3390\/jof8070727","article-title":"Postantifungal effect of antifungal drugs against Candida: what do we know and how can we apply this knowledge in the clinical setting?","volume":"8","author":"Jauregizar","year":"2022","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.riam.2026.02.001_bib1035","doi-asserted-by":"crossref","DOI":"10.1093\/jacamr\/dlad079","article-title":"Health-economic modelling of cost savings due to the use of rezafungin based on a German cost-of-illness study of candidiasis","volume":"5","author":"Jeck","year":"2023","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.riam.2026.02.001_bib1040","doi-asserted-by":"crossref","first-page":"e1011025","DOI":"10.1371\/journal.ppat.1011025","article-title":"Race and ethnicity: risk factors for fungal infections?","volume":"19","author":"Jenks","year":"2023","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.riam.2026.02.001_bib1045","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3390\/jof6040216","article-title":"Diagnosis of breakthrough fungal infections in the clinical mycology laboratory: an ECMM consensus statement","volume":"6","author":"Jenks","year":"2020","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.riam.2026.02.001_bib1050","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1080\/1120009X.2018.1557799","article-title":"Invasive fungal infection in critically ill patients: hurdles and next challenges","volume":"31","author":"Jos\u00e9","year":"2019","journal-title":"J Chemother"},{"issue":"Suppl. 1","key":"10.1016\/j.riam.2026.02.001_bib1055","doi-asserted-by":"crossref","first-page":"e14157","DOI":"10.1111\/tid.14157","article-title":"Infections after chimeric antigen receptor (CAR)-T-cell therapy for hematologic malignancies","volume":"25","author":"Kampouri","year":"2023","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.riam.2026.02.001_bib1060","doi-asserted-by":"crossref","DOI":"10.1007\/s40121-025-01120-7","article-title":"It's here, it's there, there's fungi everywhere: a case series utilizing rezafungin for invasive candidiasis","author":"Keck","year":"2025","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.riam.2026.02.001_bib1065","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1177\/00185787231206523","article-title":"Formulary drug review: rezafungin","volume":"59","author":"Kessel","year":"2024","journal-title":"Hosp Pharm"},{"key":"10.1016\/j.riam.2026.02.001_bib1070","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1136\/postgradmedj-2020-138661","article-title":"Managing drug-induced QT prolongation in clinical practice","volume":"97","author":"Khatib","year":"2021","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.riam.2026.02.001_bib1075","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.cmi.2023.05.004","article-title":"Which trial do we need? Combination treatment of Pneumocystis jirovecii pneumonia in non-HIV infected patients","volume":"29","author":"Koehler","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.riam.2026.02.001_bib1080","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1093\/cid\/cis305","article-title":"Septic shock attributed to Candida infection: importance of empiric therapy and sourcecontrol","volume":"54","author":"Kollef","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.riam.2026.02.001_bib1085","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1086\/502104","article-title":"Breakthrough candidemia in patients with cancer differs from de novo candidemia in host factors and Candida species but not intensity","volume":"23","author":"Kontoyiannis","year":"2002","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.riam.2026.02.001_bib1090","doi-asserted-by":"crossref","first-page":"863","DOI":"10.3390\/microorganisms9040863","article-title":"Comparison of in vitro killing activity of rezafungin, anidulafungin, caspofungin, and micafungin against four Candida auris clades in RPMI-1640 in the absence and presence of human serum","volume":"9","author":"Kov\u00e1cs","year":"2021","journal-title":"Microorganisms"},{"key":"10.1016\/j.riam.2026.02.001_bib1095","article-title":"New treatment options for critically important WHO fungal priority pathogens","author":"Kriegl","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.riam.2026.02.001_bib1100","doi-asserted-by":"crossref","first-page":"213","DOI":"10.5194\/jbji-9-213-2024","article-title":"Efficacy of rezafungin in a case of Candida spondylodiskitis","volume":"9","author":"Lahouati","year":"2024","journal-title":"J Bone Jt Infect"},{"key":"10.1016\/j.riam.2026.02.001_bib1105","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41572-024-00503-3","article-title":"Invasive candidiasis","volume":"10","author":"Lass-Fl\u00f6rl","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.riam.2026.02.001_bib1110","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2023.101215","article-title":"The changing epidemiology of fungal infections","volume":"94","author":"Lass-Fl\u00f6rl","year":"2023","journal-title":"Mol Aspects Med"},{"key":"10.1016\/j.riam.2026.02.001_bib1115","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s44259-023-00007-2","article-title":"Molecular mechanisms governing antifungal drug resistance","volume":"1","author":"Lee","year":"2023","journal-title":"NPJ Antimicrob Resist"},{"key":"10.1016\/j.riam.2026.02.001_bib1120","doi-asserted-by":"crossref","first-page":"e01556-19","DOI":"10.1128\/AAC.01556-19","article-title":"Determination of pharmacodynamic target exposures for rezafungin against Candida tropicalis and Candida dubliniensis in the neutropenic mouse disseminated candidiasis model","volume":"63","author":"Lepak","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2026.02.001_bib1125","doi-asserted-by":"crossref","first-page":"e01572-18","DOI":"10.1128\/AAC.01572-18","article-title":"Pharmacodynamic evaluation of rezafungin (CD101) against Candida auris in the neutropenic mouse invasive candidiasis model","volume":"62","author":"Lepak","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2026.02.001_bib1130","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/myc.12081","article-title":"Epidemiology and sites of involvement of invasive fungal infections in patients with haematological malignancies: a 20-year autopsy study","volume":"56","author":"Lewis","year":"2013","journal-title":"Mycoses"},{"key":"10.1016\/j.riam.2026.02.001_bib1135","doi-asserted-by":"crossref","first-page":"6100","DOI":"10.1128\/AAC.00620-16","article-title":"Characterization of in vitro resistance development to the novel echinocandin CD101 in Candida species","volume":"60","author":"Locke","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2026.02.001_bib1140","doi-asserted-by":"crossref","first-page":"e0158423","DOI":"10.1128\/aac.01584-23","article-title":"Outcomes by Candida spp. in the ReSTORE Phase 3 trial of rezafungin versus caspofungin for candidemia and\/or invasive candidiasis","volume":"68","author":"Locke","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2026.02.001_bib1145","article-title":"Association between duration of candidemia and clinical and healthcare resource utilization outcomes among hospitalized adult patients with candidemia who received empiric treatment with an echinocandin across United States hospitals","author":"Lodise","year":"2025","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.riam.2026.02.001_bib1150","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s11908-022-00782-5","article-title":"Antifungal resistance and the role of new therapeutic agents","volume":"24","author":"Logan","year":"2022","journal-title":"Curr Infect Dis Rep"},{"key":"10.1016\/j.riam.2026.02.001_bib1155","first-page":"3221","volume":"73","author":"Maertens","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.riam.2026.02.001_bib1160","doi-asserted-by":"crossref","first-page":"5297","DOI":"10.1128\/AAC.00980-09","article-title":"Paradoxical growth of Candida dubliniensis does not preclude in vivo response to echinocandin therapy","volume":"53","author":"Marin\u00e9","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2026.02.001_bib1165","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/blood.V96.6.2055","article-title":"Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial","volume":"96","author":"Marr","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.riam.2026.02.001_bib1170","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1086\/315193","article-title":"Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole","volume":"181","author":"Marr","year":"2000","journal-title":"J Infect Dis"},{"key":"10.1016\/j.riam.2026.02.001_bib1175","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1186\/s13054-023-04673-6","article-title":"Critical appraisal beyond clinical guidelines for intraabdominal candidiasis","volume":"27","author":"Maseda","year":"2023","journal-title":"Crit Care"},{"key":"10.1016\/j.riam.2026.02.001_bib1180","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.idc.2021.03.007","article-title":"Candidemia and invasive candidiasis","volume":"35","author":"McCarty","year":"2021","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.riam.2026.02.001_bib1185","doi-asserted-by":"crossref","first-page":"e01992-20","DOI":"10.1128\/AAC.01992-20","article-title":"Efficacy of rezafungin in prophylactic mouse models of invasive candidiasis, aspergillosis, and Pneumocystis pneumonia","volume":"65","author":"Miesel","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2026.02.001_bib1190","doi-asserted-by":"crossref","first-page":"e00546","DOI":"10.1002\/prp2.546","article-title":"Rezafungin treatment in mouse models of invasive candidiasis and aspergillosis: insights on the PK\/PD pharmacometrics of rezafungin efficacy","volume":"7","author":"Miesel","year":"2019","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.riam.2026.02.001_bib1195","doi-asserted-by":"crossref","DOI":"10.1093\/mmy\/myad021","article-title":"Real-life epidemiology and current outcomes of hospitalized adults with invasive fungal infections","volume":"61","author":"Monz\u00f3-Gallo","year":"2023","journal-title":"Med Mycol"},{"key":"10.1016\/j.riam.2026.02.001_bib1200","doi-asserted-by":"crossref","DOI":"10.1093\/jacamr\/dlae042","article-title":"Treatment of Candida glabrata native valve endocarditis with rezafungin: a case report","volume":"6","author":"Mori","year":"2024","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.riam.2026.02.001_bib1205","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1080\/14787210.2023.2203383","article-title":"The antifungal pipeline for invasive fungal diseases: what does the future hold?","volume":"21","author":"Neoh","year":"2023","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.riam.2026.02.001_bib1210","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1053\/j.ackd.2019.08.005","article-title":"Nephrotoxic chemotherapy agents: old and new","volume":"27","author":"Nicolaysen","year":"2020","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.riam.2026.02.001_bib1215","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1080\/14787210.2023.2240956","article-title":"Invasive Candida infection: epidemiology, clinical and therapeutic aspects of an evolving disease and the role of rezafungin","volume":"21","author":"Oliva","year":"2023","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.riam.2026.02.001_bib1220","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.3390\/cancers15184550","article-title":"Bispecific antibodies in hematological malignancies: a scoping review","volume":"15","author":"Omer","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.riam.2026.02.001_bib1225","doi-asserted-by":"crossref","first-page":"6872","DOI":"10.1128\/AAC.00701-16","article-title":"Preclinical evaluation of the stability, safety, and efficacy of CD101, a novel echinocandin","volume":"60","author":"Ong","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2026.02.001_bib1230","doi-asserted-by":"crossref","first-page":"e407","DOI":"10.3324\/haematol.2017.172536","article-title":"Changes in the incidence of candidemia and related mortality in patients with hematologic malignancies in the last ten years. A SEIFEM 2015-B report","volume":"102","author":"Pagano","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.riam.2026.02.001_bib1235","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.riam.2026.02.001_bib1240","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-030-23765-3_1","article-title":"Current development of monoclonal antibodies in cancer therapy","volume":"214","author":"Parakh","year":"2020","journal-title":"Recent Results Cancer Res"},{"key":"10.1016\/j.riam.2026.02.001_bib1245","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1093\/jac\/dks019","article-title":"Epidemiology, species distribution and in vitro antifungal susceptibility of fungaemia in a Spanish multicentre prospective survey","volume":"67","author":"Pem\u00e1n","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.riam.2026.02.001_bib1250","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.riam.2020.07.001","article-title":"Fungal co-infection in COVID-19 patients: should we be concerned?","volume":"37","author":"Pem\u00e1n","year":"2020","journal-title":"Rev Iberoam Micol"},{"key":"10.1016\/j.riam.2026.02.001_bib1255","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00099-20","article-title":"Activity of a long-acting echinocandin, rezafungin, and comparator antifungal agents tested against contemporary invasive fungal isolates (SENTRY Program, 2016\u20132018)","volume":"64","author":"Pfaller","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2026.02.001_bib1260","doi-asserted-by":"crossref","first-page":"e0075024","DOI":"10.1128\/aac.00750-24","article-title":"Safety of rezafungin as a long-term treatment option in two patients with complicated fungal infections: two cases from Lecco Hospital (Italy)","volume":"68","author":"Ponta","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2026.02.001_bib1265","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1111\/myc.13130","article-title":"Candidaemia in haematological malignancy patients from a SEIFEM study: epidemiological patterns according to antifungal prophylaxis","volume":"63","author":"Posteraro","year":"2020","journal-title":"Mycoses"},{"key":"10.1016\/j.riam.2026.02.001_bib1270","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jinf.2023.05.005","article-title":"Breakthrough invasive fungal infection among patients with haematologic malignancies: a national, prospective, and multicentre study","volume":"87","author":"Puerta-Alcalde","year":"2023","journal-title":"J Infect"},{"key":"10.1016\/j.riam.2026.02.001_bib1275","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1097\/CCM.0000000000000221","article-title":"Impact of therapeutic strategies on the prognosis of candidemia in the ICU","volume":"42","author":"Puig-Asensio","year":"2014","journal-title":"Crit Care Med"},{"key":"10.1016\/j.riam.2026.02.001_bib1280","first-page":"e172","article-title":"Therapeutic tools for oral candidiasis: current and new antifungal drugs","volume":"24","author":"Quind\u00f3s","year":"2019","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"10.1016\/j.riam.2026.02.001_bib1285","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s10123-018-0014-1","article-title":"The continuous changes in the aetiology and epidemiology of invasive candidiasis: from familiar Candida albicans to multiresistant Candida auris","volume":"21","author":"Quind\u00f3s","year":"2018","journal-title":"Int Microbiol"},{"key":"10.1016\/j.riam.2026.02.001_bib1290","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.riam.2013.10.001","article-title":"Epidemiology of candidaemia and invasive candidiasis. A changing face","volume":"31","author":"Quind\u00f3s","year":"2014","journal-title":"Rev Iberoam Micol"},{"key":"10.1016\/j.riam.2026.02.001_bib1295","first-page":"1","article-title":"New pharmacotherapeutic strategies for drug-resistant Candida infections: a review","author":"Raposa","year":"2025","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.riam.2026.02.001_bib1300","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1056\/NEJMoa066906","article-title":"Anidulafungin versus fluconazole for invasive candidiasis","volume":"356","author":"Reboli","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.riam.2026.02.001_bib1305","doi-asserted-by":"crossref","first-page":"e0091623","DOI":"10.1128\/aac.00916-23","article-title":"Population pharmacokinetic modeling and target attainment analyses of rezafungin for the treatment of candidemia and invasive candidiasis","volume":"67","author":"Roepcke","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2026.02.001_bib1310","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/joim.13697","article-title":"Novel precision medicine approaches and treatment strategies in hematological malignancies","volume":"294","author":"Rosenquist","year":"2023","journal-title":"J Intern Med"},{"key":"10.1016\/j.riam.2026.02.001_bib1315","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2024.106229","article-title":"Attributable mortality of candidemia \u2013 results from the ECMM Candida III multinational European Observational Cohort Study","volume":"89","author":"Salmanton-Garc\u00eda","year":"2024","journal-title":"J Infect"},{"key":"10.1016\/j.riam.2026.02.001_bib1320","doi-asserted-by":"crossref","first-page":"e01627-16","DOI":"10.1128\/AAC.01627-16","article-title":"Safety and pharmacokinetics of CD101 IV, a novel echinocandin, in healthy adults","volume":"61","author":"Sandison","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2026.02.001_bib1325","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/myc.12788","article-title":"The diagnosis and treatment of invasive aspergillosis in Dutch haematology units facing a rapidly increasing prevalence of azole-resistance: a nationwide survey and rationale for the DB-MSG 002 study protocol","volume":"61","author":"Schauwvlieghe","year":"2018","journal-title":"Mycoses"},{"key":"10.1016\/j.riam.2026.02.001_bib1330","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s12281-021-00419-5","article-title":"Investigational agents for the treatment of resistant yeasts and molds","volume":"15","author":"Seiler","year":"2021","journal-title":"Curr Fungal Infect Rep"},{"key":"10.1016\/j.riam.2026.02.001_bib1335","doi-asserted-by":"crossref","first-page":"e14283","DOI":"10.1111\/tid.14283","article-title":"Managing infectious challenges in the age of molecular-targeted therapies for adult hematological malignancies","volume":"26","author":"Shah","year":"2024","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.riam.2026.02.001_bib1340","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1093\/infdis\/171.6.1545","article-title":"Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation \u2013 a prospective, randomized, double-blind study","volume":"171","author":"Slavin","year":"1995","journal-title":"J Infect Dis"},{"key":"10.1016\/j.riam.2026.02.001_bib1345","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/infdis\/jiae146","article-title":"Regulatory considerations in the approval of Rezafungin (Rezzayo) for the treatment of candidemia and invasive candidiasis in adults","volume":"230","author":"Smith","year":"2024","journal-title":"J Infect Dis"},{"key":"10.1016\/j.riam.2026.02.001_bib1350","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/cid\/ciae363","article-title":"Treatment outcomes among patients with a positive Candida culture close to randomization receiving rezafungin or caspofungin in the ReSTORE study","volume":"79","author":"Soriano","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.riam.2026.02.001_bib1355","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1093\/jac\/dkad139","article-title":"Invasive candidiasis: current clinical challenges and unmet needs in adult populations","volume":"78","author":"Soriano","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.riam.2026.02.001_bib1360","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.cmi.2024.11.029","article-title":"Clinical and mycological outcomes of candidaemia and\/or invasive candidiasis by Candida spp. and antifungal susceptibility: pooled analyses of two randomized trials of rezafungin versus caspofungin","volume":"31","author":"Soriano","year":"2025","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.riam.2026.02.001_bib1365","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2023.101190","article-title":"Antifungal prophylaxis and pre-emptive therapy: when and how?","volume":"92","author":"Sprute","year":"2023","journal-title":"Mol Aspects Med"},{"key":"10.1016\/j.riam.2026.02.001_bib1370","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s12281-020-00370-x","article-title":"Extrapolating antifungal animal data to humans: is it reliable?","volume":"14","author":"Stevens","year":"2020","journal-title":"Curr Fungal Infect Rep"},{"key":"10.1016\/j.riam.2026.02.001_bib1375","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s40265-023-01891-8","article-title":"Rezafungin: first approval","volume":"83","author":"Syed","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.riam.2026.02.001_bib1380","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0140-6736(22)02324-8","article-title":"Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial","volume":"401","author":"Thompson","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.riam.2026.02.001_bib1385","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1473-3099(23)00551-0","article-title":"Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: pooled data from two prospective randomised controlled trials","volume":"24","author":"Thompson","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.riam.2026.02.001_bib1390","doi-asserted-by":"crossref","first-page":"e3647","DOI":"10.1093\/cid\/ciaa1380","article-title":"Rezafungin versus caspofungin in a phase 2, randomized, double-blind study for the treatment of candidemia and invasive candidiasis: The STRIVE trial","volume":"73","author":"Thompson","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.riam.2026.02.001_bib1395","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1093\/jac\/dkz390","article-title":"In vitro activity of rezafungin against common and rare Candida species and Saccharomyces cerevisiae","volume":"74","author":"T\u00f3th","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.riam.2026.02.001_bib1400","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaf034","article-title":"Long-term safety and effectiveness of rezafungin treatment in candidemia and invasive candidiasis: results from an early access program in Italy and Germany","volume":"12","author":"Trapani","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.riam.2026.02.001_bib1405","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa061098","article-title":"Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease","volume":"356","author":"Ullmann","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.riam.2026.02.001_bib1410","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3390\/microorganisms12050903","article-title":"Salvage Therapy with rezafungin for Candida parapsilosis spondylodiscitis: a case report from expanded access program","volume":"12","author":"Viceconte","year":"2024","journal-title":"Microorganisms"},{"key":"10.1016\/j.riam.2026.02.001_bib1415","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.vhri.2019.07.002","article-title":"The economic burden of candidemia and invasive candidiasis: a systematic review","volume":"21","author":"Wan Ismail","year":"2020","journal-title":"Value Health Reg Issues"},{"key":"10.1016\/j.riam.2026.02.001_bib1420","series-title":"WHO fungal priority pathogens list to guide research, development and public health action","year":"2022"},{"key":"10.1016\/j.riam.2026.02.001_bib1425","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1093\/jac\/dky280","article-title":"Rezafungin (CD101) demonstrates potent in vitro activity against Aspergillus, including azole-resistant Aspergillus fumigatus isolates and cryptic species","volume":"73","author":"Wiederhold","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.riam.2026.02.001_bib1430","doi-asserted-by":"crossref","first-page":"e01165-19","DOI":"10.1128\/AAC.01165-19","article-title":"Extended-interval dosing of rezafungin against azole-resistant Aspergillus fumigatus","volume":"63","author":"Wiederhold","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2026.02.001_bib1435","doi-asserted-by":"crossref","first-page":"5111","DOI":"10.1182\/blood-2010-02-268151","article-title":"Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation","volume":"116","author":"Wingard","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.riam.2026.02.001_bib1440","doi-asserted-by":"crossref","first-page":"e0112924","DOI":"10.1128\/jcm.01129-24","article-title":"Anidulafungin is a useful surrogate marker for predicting in vitro susceptibility to rezafungin among five Candida species using CLSI methods and interpretive criteria","volume":"63","author":"Winkler","year":"2025","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.riam.2026.02.001_bib1445","doi-asserted-by":"crossref","first-page":"e70001","DOI":"10.1111\/myc.70001","article-title":"The in vitro activity of rezafungin against uncommon species of Candida","volume":"67","author":"Winkler","year":"2024","journal-title":"Mycoses"},{"key":"10.1016\/j.riam.2026.02.001_bib1450","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.riam.2024.11.001","article-title":"Antifungal pipeline: new tools for the treatment of mycoses","volume":"41","author":"Wolfgruber","year":"2024","journal-title":"Rev Iberoam Micol"},{"key":"10.1016\/j.riam.2026.02.001_bib1455","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s11046-024-00871-0","article-title":"Insights from three pan-European multicentre studies on invasive Candida infections and outlook to ECMM Candida IV","volume":"189","author":"Wolfgruber","year":"2024","journal-title":"Mycopathologia"},{"key":"10.1016\/j.riam.2026.02.001_bib1460","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/21501203.2019.1614106","article-title":"Current insights into fungal species diversity and perspective on naming the environmental DNA sequences of fungi","volume":"10","author":"Wu","year":"2019","journal-title":"Mycology"},{"key":"10.1016\/j.riam.2026.02.001_bib1465","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3390\/jof10060397","article-title":"In vitro activitiy of rezafungin in comparison with anidulafungin and caspofungin against invasive fungal isolates (2017\u20132022) in China","volume":"10","author":"Yang","year":"2024","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.riam.2026.02.001_bib1470","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.riam.2017.03.008","article-title":"EPICO 4.0. \u2018Total quality\u2019 in the management of invasive candidiasis in critically ill patients by analysing the integrated process","volume":"34","author":"Zaragoza","year":"2017","journal-title":"Rev Iberoam Micol"},{"key":"10.1016\/j.riam.2026.02.001_bib1475","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.riam.2021.04.006","article-title":"Tratamiento antif\u00fangico individualizado en el paciente cr\u00edtico con infecci\u00f3n f\u00fangica invasora","volume":"38","author":"Zaragoza","year":"2021","journal-title":"Rev Iberoam Micol"},{"key":"10.1016\/j.riam.2026.02.001_bib1480","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3390\/jof6040192","article-title":"Review of the novel echinocandin antifungal rezafungin: animal studies and clinical data","volume":"6","author":"Zhao","year":"2020","journal-title":"J Fungi (Basel)"}],"container-title":["Revista Iberoamericana de Micolog\u00eda"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130140626000112?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130140626000112?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T12:11:45Z","timestamp":1781525505000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1130140626000112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":148,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1130140626000112"],"URL":"https:\/\/doi.org\/10.1016\/j.riam.2026.02.001","relation":{},"ISSN":["1130-1406"],"issn-type":[{"value":"1130-1406","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antifungal activity of rezafungin in invasive candidiasis: From bench to bed","name":"articletitle","label":"Article Title"},{"value":"Revista Iberoamericana de Micolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.riam.2026.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Asociaci\u00f3n Espa\u00f1ola de Micolog\u00eda.","name":"copyright","label":"Copyright"}]}}